Health Care·Biotechnology·$161.9B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.52 | N/A | +10.64% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.52 | N/A | +10.64% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a positive outlook regarding their product performance while remaining aware of potential market headwinds.
Management highlighted the strong performance in their key therapeutic areas.
They expressed confidence in their pipeline but acknowledged market challenges.
Gilead Sciences reported better-than-expected earnings per share, indicating strong operational performance. However, the lack of revenue data and guidance may leave investors cautious. The stock's reaction is currently unavailable, reflecting uncertainty in market sentiment.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
SEAGATE TECHNOLOGY H
Oct 28, 2013